In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Harrow Health (HROW – Research Report). The company’s shares closed last Friday at $11.60.
Knickerbocker covers the Healthcare sector, focusing on stocks such as Ironwood Pharma, Xtant Medical Holdings, and Avadel Pharmaceuticals. According to TipRanks, Knickerbocker has an average return of 3.3% and a 49.37% success rate on recommended stocks.
Currently, the analyst consensus on Harrow Health is a Strong Buy with an average price target of $23.00, implying a 98.28% upside from current levels. In a report released on May 10, B.Riley Financial also reiterated a Buy rating on the stock with a $26.00 price target.
HROW market cap is currently $410.4M and has a P/E ratio of -15.57.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HROW in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harrow Health (HROW) Company Description:
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
Read More on HROW:
